Beijing Institute of Biological Products Co., Ltd. (BIBP), a subsidiary of China National Biotec Group Company Limited (CNBG), China National Pharmaceutical Group Co., Ltd. (Sinopharm), is engaged in the research, production and marketing of vaccines, diagnostic preparations and other biological products, with a registered capital of CNY 2.3 billions. The history of BIBP can be traced back to 1919 when National Epidemic Prevention Bureau was established by the Beiyang Government, representing the cradle of biological products for The People's Republic of China. BIBP, covering an area of 158,000 square meters, is located in Beijing Economic-Technological Development Area, which is considered as the largest vaccine production base under immunization planning in China, and as the first biological product production company in China to obtain the title of "Green Factory" from the Ministry of Industry and Information Technology of China and from Beijing Municipal Government. Our products cover viral vaccines, bacterial vaccines and genetic engineering vaccines, as well as combined and multivalent vaccines such as MMR, DTP, poliomyelitis vaccine and Inactivated COVID-19 vaccine (Vero Cell), with an annual production capacity of more than 5 billion doses. Among them, the bOPV, sIPV and Inactivated COVID-19 vaccine (Vero Cell) have been approved for WHO PQ/EUL, and exported to more than 120 countries and regions around the world, and are well recognized by various international organizations and governments.